gmp
gmp

Find Approved Drugs for Infections and Infectious Diseases in Clinical Development in ISRAEL

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Hypromellose

            Therapeutic Area: Infections and Infectious Diseases Product Name: TaffiX

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 13, 2020

            Details:

            Data from a prospective clinical post marketing users survey shows that TaffixTM effectively blocks viruses from reaching nasal mucosa and was able to reduce infection rate of SARS-CoV-2 virus after super spread event by at least 4 fold.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Emtricitabine,Tenofovir Disoproxil Fumarate

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 02, 2020

            Details:

            Emtricitabine and Tenofovir Disoproxil Fumarate Tablets and Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets are both combination treatments available as a single pill with similar safety profiles to their reference products.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Omeprazole Magnesium,Amoxicillin,Rifabutin

            Therapeutic Area: Infections and Infectious Diseases Product Name: Talicia

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cosmo Pharmaceuticals

            Deal Size: $21.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement August 13, 2020

            Details:

            Pursuant to the agreement, the companies will co-develop a novel next-generation therapy for the eradication of H. pylori infection. Cosmo is to receive the exclusive European rights to the new drug.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Hypromellose

            Therapeutic Area: Infections and Infectious Diseases Product Name: TaffiX

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 07, 2020

            Details:

            Gel layer produced by TaffiX® powder after administration of a clinical equivalent amount, effectively blocked SARS-CoV-2 virus, as demonstrated by four log reduction in amount of viral RNA and reduced the amount of infectious live virus by more than 99%­­­.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Omeprazole Magnesium,Amoxicillin,Rifabutin

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: HealthCare Royalty Partners

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Financing February 25, 2020

            Details:

            The non-dilutive financing will support the acquisition of rights to Movantik® from AstraZeneca, the planned U.S. launch of Talicia® this quarter and the ongoing promotion of Aemcolo®.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Omeprazole Magnesium,Amoxicillin,Rifabutin

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Entera Health

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Termination Agreement January 21, 2020

            Details:

            RedHill provided a notice of termination to Entera Health regarding the license agreement for EnteraGam® and the co-promotion agreement with Advanz Pharma Corp. for Donnatal® will not be renewed.